D68.311 Acquired hemophilia

Name of the Condition

• Acquired hemophilia

Summary

Acquired hemophilia is a rare bleeding disorder characterized by the sudden onset of bleeding due to the development of autoantibodies that target and inhibit clotting factors, most commonly factor VIII. Unlike congenital hemophilia, it occurs in individuals without a prior history of bleeding disorders and is not inherited. The condition disrupts the coagulation cascade, leading to impaired clot formation and excessive bleeding.

Causes

The primary cause is the production of autoantibodies (inhibitors) against clotting factors, typically factor VIII, by the immune system. These antibodies neutralize the factor's function, preventing normal clot formation. The exact trigger for this immune response is often unknown but may involve underlying conditions or events that stimulate antibody production.

Risk Factors

• Autoimmune disorders
• Certain cancers
• Infections
• Pregnancy or postpartum period
• Advanced age
• Patients with no prior bleeding history

Symptoms

• Unexplained or excessive bruising
• Prolonged bleeding from cuts
• Joint or muscle bleeds
• Heavy menstrual periods
• Gastrointestinal bleeding
• Spontaneous bleeding without injury

Diagnosis

Diagnosis involves clinical evaluation and laboratory tests. Blood tests measure clotting factor levels, detect specific antibodies or inhibitors, and assess coagulation function using tests like prothrombin time (PT) and activated partial thromboplastin time (aPTT). Mixing studies and inhibitor assays help confirm the presence and type of inhibitor.

Treatment Options

• Administration of clotting factor concentrates (bypassing agents)
• Immunosuppressive drugs to reduce antibody production
• Plasmapheresis to remove inhibitors
• Avoidance of physical activities that may lead to injury
• Management of bleeding episodes with supportive care

Prognosis and Follow-Up

Prognosis depends on the underlying cause, severity of bleeding, and response to treatment. Most patients achieve remission with immunosuppressive therapy, but relapses can occur. Regular follow-up is necessary to monitor for inhibitor recurrence and manage complications. Long-term outcomes are generally favorable with appropriate treatment.

Complications

• Severe or life-threatening bleeding
• Joint damage from recurrent bleeds
• Organ damage from internal bleeding
• Treatment-related side effects (e.g., infection from immunosuppression)

Lifestyle & Prevention

• Avoid activities with high injury risk
• Use protective gear during sports or physical activities
• Maintain regular medical check-ups
• Promptly report any unusual bleeding to healthcare providers

When to Seek Professional Help

Seek immediate medical attention for:

• Uncontrolled or excessive bleeding
• Signs of internal bleeding (e.g., severe pain, swelling, dizziness)
• Sudden onset of bruising or bleeding without injury
• Heavy or prolonged menstrual bleeding

Tips for Medical Coders

Document the clinical presentation, including bleeding episodes, laboratory findings (e.g., inhibitor levels), and underlying conditions. Ensure the code D68.311 is used for acquired hemophilia, and specify any associated factors or complications. Include details on treatment and response to support accurate coding and clinical context.